These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30213396)

  • 1. Evolving treatment strategies in mantle cell lymphoma.
    Edwin NC; Kahl B
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):270-278. PubMed ID: 30213396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.
    Patel DA; Wan F; Trinkaus K; Guy DG; Edwin N; Watkins M; Bartlett NL; Cashen A; Fehniger TA; Ghobadi A; Shah NM; Kahl BS
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):552-560. PubMed ID: 37183115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma.
    Guy D; Kahl BS
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):861-870. PubMed ID: 32861283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine-rituximab in mantle cell lymphoma.
    Lipsky A; Martin P
    Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment strategies in mantle cell lymphoma.
    Maddocks K; Blum KA
    Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal initial management of the older MCL patient?
    Kluin-Nelemans JC; Doorduijn JK
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):99-104. PubMed ID: 29452672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    McCulloch R; Visco C; Eyre TA; Frewin R; Phillips N; Tucker DL; Quaglia FM; McMillan A; Lambert J; Crosbie N; Rule S
    Br J Haematol; 2020 May; 189(4):684-688. PubMed ID: 32011729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
    Armand P; Redd R; Bsat J; Mayuram S; Giardino A; Fisher DC; LaCasce AS; Jacobson C; Davids MS; Brown JR; Weng L; Wilkins J; Faham M; Freedman AS; Joyce R; Jacobsen ED
    Br J Haematol; 2016 Apr; 173(1):89-95. PubMed ID: 26729345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma - Current standards of care and future directions.
    Martin P; Ghione P; Dreyling M
    Cancer Treat Rev; 2017 Jul; 58():51-60. PubMed ID: 28651117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Romancik JT; Cohen JB
    Curr Treat Options Oncol; 2021 Nov; 22(12):118. PubMed ID: 34812968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
    Smith SD; Gandhy S; Gopal AK; Reddy P; Shadman M; Till BG; Lynch RC; Kanan S; Cowan A; Low L; Hill BT
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):48-52. PubMed ID: 30409719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population.
    Yang X; Khoo LP; Chang EWY; Yang VS; Poon E; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
    BMC Cancer; 2021 May; 21(1):566. PubMed ID: 34001056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.
    Cohen JB; Zain JM; Kahl BS
    Am Soc Clin Oncol Educ Book; 2017; 37():512-525. PubMed ID: 28561694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current treatment strategy in mantle cell lymphoma].
    Ogura M
    Nihon Rinsho; 2014 Mar; 72(3):499-511. PubMed ID: 24724411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
    Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
    Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.